ABM Therapeutics

Biotechnology Research • San Diego, California, United States • 1-10 Employees

Company overview

Headquarters	4445 Eastgate Mall, San Diego, California 92121, US
Website	abmtx.com
NAICS	541714
Founded	2015
Employees	1-10
Socials

Key Contact at ABM Therapeutics

Chen Chen

Chief Executive Officer

ABM Therapeutics Email Formats

ABM Therapeutics uses 1 email format. The most common is {last name}{last name} (e.g., doedoe@abmtx.com), used 100% of the time.

Format	Example	Percentage
{last name}{last name}	doedoe@abmtx.com	100%

About ABM Therapeutics

ABM is an innovative drug discovery and development company focusing on small molecule targeted therapy for the possible treatments of brain cancers including GBM, as well as brain metastasis from melanoma, lung cancer, and breast cancer. It was founded in 2015 by a group of biotech and pharmaceutical industry veterans with more than 20 years of experience in the development of neurological drugs and enterprise management from North America. Since establishment, ABM is building its broad proprietary pipeline internally to construct a brain medicine R&D platform through collaborations with CROs and partners. Our leading program ABM-1310, is highly potent and selective BRAF inhibitor with an excellent cell permeability and brain penetration. The compound was designed to address cancers with BRAFV600 mutation. BRAF mutation happens in about 8% total cancers, such as colorectal cancer, melanoma drug resistance and brain metastasis, and glioma (current drugs are limited by poor brain penetration), as potentially the best-in-class. It was granted the Investigational New Drug (IND) approval in November 2019 in the USA. (Clinical trial information: NCT04190628) More information about ABM’s ongoing ABM-1310 trial is available at www.ClinicalTrials.gov and on the company website at www.abmtx.com. ABM-1310 also got IND approval by NMPA in China in November 2021. ABM-168 is a potent allosteric MEK inhibitor with good cell permeability and BBB penetration. Our approach is to combine ABM-168 with another oncogenic driver inhibitor such as a BRAF inhibitor. The compound received IND approval by FDA in Oct. 2022.

ABM Therapeutics revenue & valuation

Annual revenue	$598,885
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$2,000,000
Total funding	$30,000,000

Employees by Management Level

Total employees: 1-10

Seniority

Employees

C-Suite

Employees by Department

ABM Therapeutics has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

Explore ABM Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2022-02-04	5	$30,000,000

Funding Insights

$30,000,000

Total funding amount

$30,000,000

Most recent funding amount

Number of funding rounds

Frequently asked questions

ABM Therapeutics is located in San Diego, California, US.

ABM Therapeutics was founded in 2015, making it 11 years old. The company has established itself as a significant player in its industry over this time.

ABM Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

ABM Therapeutics has raised a total of $30,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.

Key Contact at ABM Therapeutics

Chen Chen

Chief Executive Officer

4.8

40,000 users